A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 685 participants.

Also called NCT01217073

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 685 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01217073
  • EudraCT 2010-022193-13
  • EudraCT 2011-000656-42
Main results
  • Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes Diabetes care, 2015-11 DOI, PubMed 26310692

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01217073. Randomized; triple masking; primary purpose treatment. Start 2010-10-08 (actual); primary completion 2012-01-03 (actual). Results posted on 2015-10-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Placebo to omarigliptin
Intervention (Drug)
Pioglitazone
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo to metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01217073
Content hash
cd87ac84e84d4353d798017b1813ff3c88e089488ea888d9cd5fb8fb37041ddb